Pasithea Therapeutics Corp. Common Stock (KTTA)

About KTTA

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

www.pasithea.com/

Fundamentals

1-day range

$0.5416$0.6043

Market cap

$14.92M

P/E (trailing)

—

P/E (forward)

-1.22

EPS (trailing)

$-1.98

Dividend yield

—

Beta

0.31

Avg. volume

753.5K

Forecasts

1 analyst ratings

Pasithea Therapeutics Corp. Common Stock Competitors

Chosen by industry and closest market cap.

• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.92MP/E —
  $0.281$2.06
• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $15.11MP/E —
  $1.03$8.48
• KALA

  KALA BIO Inc. Common Stock

  $0.6949

  ▼ 14.42%
  Market cap $15.14MP/E —
  $0.5867$1,030
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• MDCX

  Medicus Pharma Ltd. Common Stock

  $0.258

  ▼ 3.73%
  Market cap $16.60MP/E —
  $0.2425$3.05
• OPTH

  Optimi Health Corp. Common Shares

  $4.93

  ▼ 0.80%
  Market cap $16.61MP/E —
  $0.195$11.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Friday's After-Market Session
  Benzinga · 8/21/2026

• Coastlands Capital LP · June 17, 2026 · Buy

  100.0K @ $0.53
• Marques Tiago · May 1, 2026 · Grant

  1.76M
• Dumesnil Simon · May 1, 2026 · Grant

  152.8K
• Krishnan Kartik · May 1, 2026 · Grant

  1.13M
• Leahy Emer · May 1, 2026 · Grant

  152.8K
• Schneiderman Daniel H · May 1, 2026 · Grant

  1.13M
• Novak Alfred J · May 1, 2026 · Grant

  152.8K
• Lawrence Steinman · May 1, 2026 · Grant

  152.8K

Institutional Ownership

March 31, 2026

Total shares held

12.77M

Total value held

$9.48M

Institutional holders

19